Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
Jonathan K ReynoldsWashington State University, College of Pharmacy, Pullman, WA, USAAbstract: JanumetTM, a fixed dose combination of sitagliptin/metformin HCL manufactured by Merck Pharmaceuticals, has received US Food and Drug Administration approval for treatment of patients with type 2 diabetes,...
Main Author: | Jonathan K Reynolds |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2009-07-01
|
Series: | Diabetes, Metabolic Syndrome and Obesity |
Online Access: | http://www.dovepress.com/fixed-dose-combination-of-sitagliptin-and-metformin-for-the-treatment--a3384 |
Similar Items
-
Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
by: Green J, et al.
Published: (2010-10-01) -
Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
by: Karen Barnard, et al.
Published: (2010-10-01) -
Efficacy and safety of fixed dose combination of Sitagliptin, metformin, and pioglitazone in type 2 Diabetes (IMPACT study): a randomized controlled trial
by: Mondal Aashish, et al.
Published: (2024-02-01) -
Efficacy, Safety and Treatment Satisfaction of Glimepiride vs Sitagliptin in Combination with Metformin in Type 2 Diabetes Mellitus
by: Subodh Kumar, et al.
Published: (2015-12-01) -
Efficacy and safety of metformin-sitagliptin combination for the treatment of patients with diabetes mellitus and obesity
by: Alexander Sergeevich Ametov, et al.
Published: (2010-09-01)